A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder

Archives of General Psychiatry

Volumn 53, Issue 11, 1996, Pages 1001-1008

  McDougle, Christopher J ^a,b,c   Naylor, Susan T ^a,b   Cohen, Donald J ^b,c   Volkmar, Fred R ^c   Heninger, George R ^a,b   Price, Lawrence H ^a,b  

^a Yale University School of Medicine   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSION; ARTICLE; AUTISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SEDATION; SEROTONIN UPTAKE; SOCIAL ADAPTATION; TREATMENT OUTCOME;

EID: 0029803880     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1996.01830110037005     Document Type: Article

References (64)

1. Kanner L. Autistic disturbances of affective contact. J Nerv Child. 1943;2:217-250.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
3. Rapin I. Introduction and overview. In: Bauman ML, Kemper TL, eds. The Neurobiology of Autism. Baltimore, Md: The Johns Hopkins University Press; 1994: 1-17.
4. Wing L. Diagnosis and Treatment of Autism. New York, NY: Plenum Publishing Corp; 1989.
5. Runenstein JLR, Lotspeich L, Ciaranello RD. The neurobiology of developmental disorders. In: Lahey BB, Kazdin AE, eds. Advances in Clinical Child Psychology. New York, NY: Plenum Publishing Corp; 1990;13:1-52.
6. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961;58:315-320.
7. Anderson GM, Freedman DX, Cohen DJ, Volkmar FR, Hoder EL, McPhedran P, Minderaa RB, Hansen CR, Young JG. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry. 1987;28:885-900.
8. Todd RD, Ciaranello RD. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci U S A. 1985:82:612-616.
9. Yuwiler A, Shih JC, Chen C-H, Ritvo ER, Hanna G, Ellison GW, King BH. Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. J Autism Dev Disord. 1992;22:33-45.
10. Cook EH Jr, Perry BD, Dawson G, Wainwright MS, Leventhal BL. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects. J Autism Dev Disord. 1993;23:67-78.
11. Hoshino Y, Tachibana JR, Watanabe M, Murata S, Yokoyama F, Kaneko M, Yashima Y, Kumoshiro H. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction. Jpn J Psychiatry Neurol. 1984;26:937-945.
12. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ. Serotonergic responsivity in male young adults with autistic disorder: results of a pilot study. Arch Gen Psychiatry. 1989;46:213-221.
13. McDougle CJ, Naylor ST, Cohen DJ, Aghajanian GK, Heninger GR, Price LH. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry. 1996;53:993-1000.
14. McDougle CJ, Price LH, Volkmar FR. Recent advances in the pharmaco-therapy of autism and related conditions. In: Volkmar FR, ed. Psychoses and Pervasive Developmental Disorders. Philadelphia, Pa: WB Saunders Co; 1994; 3:71-89.
15. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry. 1978;17:640-655.
16. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251-255.
17. Geller E, Ritvo E, Freeman B, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med. 1982;307:165-169.
18. Campbell M. Fenfluramine treatment of autism. J Child Psychol Psychiatry. 1988;29:1-10.
19. Campbell M, Adams P, Small AM, Curren EL, Overall J, Anderson LT, Lynch N, Perry R. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:434-439.
20. Ekman G, Miranda-Linné F, Gillberg C, Garle M, Wetterberg L. Fenfluramine treatment of twenty children with autism. J Autism Dev Disord. 1989;19:511-532.
21. Sherman J, Factor D, Swinson R, Darjes R. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord. 1989;19:533-543.
22. Duker P, Welles K, Seys D, Rensen H, Vis A. Brief report: effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals. J Autism Dev Disord. 1991;21:355-363.
23. Schuster C, Lewis M, Seiden L. Fenfluramine: neurotoxicity. Psychopharmacol Bull. 1986;22:148-151.
24. Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, Foltz RL, Monti KM, Perry R, Nobler M, Roberts E. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry. 1989;28:200-206.
25. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32:1283-1291.
26. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof GJ, van Engeland H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind, placebo-controlled studies. Arch Gen Psychiatry. 1995;52:766-773.
27. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990;20:537-543.
28. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739-745.
29. Mehlinger R, Scheftner WA, Poznanski E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatry. 1990;29:985.
30. Hamdan-Allen G. Brief report: trichotillomania in an autistic male. J Autism Dev Disord. 1991;21:79-82.
31. Todd RD. Fluoxetine in autism. Am J Psychiatry. 1991;148:1089.
32. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:3.
33. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31:746-750.
34. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.
35. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry. 1993;32:792-797.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
37. World Health Organization. International Statistical Classification of Diseases, 10th Revision (ICD-10). Geneva, Switzerland: World Health Organization; 1992.
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, US Dept of Health, Education and Welfare: 1976. Publication 76-338.
39. Le Couteur A, Rutter M, Lord C, Rios P, Robertson S, Holdgrafer M, McLennan J. Autism Diagnostic Interview: a standardized investigator-based instrument. J Autism Dev Disord. 1989;19:363-387.
40. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, Schopler E. Autism Diagnostic Observation Schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989;19:185-212.
41. Krug DA, Arick JR, Almond PJ. Autism Screening Instrument for Education Planning. Portland, Ore: ASIEP Educational Co; 1980.
42. Wechsler D. Manual for the Wechsler Adult Intelligence Scale - Revised. San Antonio, Tex: The Psychological Corp; 1981.
43. Leiter RG. Leiter International Performance Scale. Chicago, III: Stoelting Co; 1948.
44. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1993;24:203-220.
45. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann R, Hill C, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS), I: development, use, and reliability. Arch Gen Psychiatry. 1989;46: 1006-1011.
46. McDougle CJ, Kresch L, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry. 1995;152:772-777.
47. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatr Res. 1979; 1:131-139.
48. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry. 1986;25:130-136.
49. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales. Circle Pines, Minn: American Guidance Service; 1984.
50. Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry. 1990;1:127-129.
51. Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry. 1989;46:36-43.
52. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;47:577-585.
53. Kruesi MJ, Rapoport JL, Hamburger S, Hibbs E, Potter WZ, Lenane M, Brown GL. Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry. 1990;47:419-426.
54. Kruesi MJ, Hibbs ED, Zahn TP, Keysor CS, Hamburger SD, Bartko JJ, Rapoport JL. A 2-year prospective follow-up study of children and adolescents with disruptive behavior disorders: prediction by cerebrospinal fluid 5-hydroxyindoleacetic acid, homovanillic acid, and autonomic measures? Arch Gen Psychiatry. 1992;49:429-435.
55. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983;33:2609-2614.
56. Mehlman PT, Higley JD, Faucher I, Lilly AA, Taub DM, Vickers J, Suomi SJ, Linnoila M. Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. Am J Psychiatry. 1994;151: 1485-1491.
57. Cohen DJ, Shaywitz BA, Johnson WT, Bowers MB. Biogenic amines in autistic and atypical children: cerebrospinal fluid measures of homovanillic acid and 5-hydroxyirdoleacetic acid. Arch Gen Psychiatry. 1974;31:845-853.
58. Narayan M, Srinath S, Anderson GM, Meundi DB. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993;33:630-635.
59. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol. 1992;12:27-31.
60. Kelley LA, Hellings JA, Gabrielli WF, Kilgore E. Sertraline response in mentally retarded adults. Presented at the American Psychiatric Association 146th Annual Meeting; May 22-27, 1993; San Francisco, Calif.
61. Garber HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992;31:1157-1160.
62. Volkmar FR. Social development. In: Cohen D, Donnellan A, eds. Handbook of Autism and Pervasive Developmental Disorders. New York, NY: John Wiley & Sons Inc; 1987:41-60.
63. Brammer GL, Raleigh MJ, McGuire MT. Physiological and behavioral relationships in individually-housed male vervet monkeys. Am J Primatol. 1984;6: 400.
64. Raleigh MJ, Brammer GL, Yuwiler A, Flannery JW, McGuire MT, Geller E. Serotonergic influences on the social behavior of vervet monkeys (Cercopithecus aethiops sabaeus). Exp Neurol. 1980;68:322-324.